Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rivastigmine
Drug ID BADD_D01955
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status approved; investigational
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D03822
MeSH ID D000068836
PubChem ID 77991
TTD Drug ID D0WY5Q
NDC Product Code 16714-117; 70710-1198; 72855-101; 0781-7304; 65372-1153; 82245-0107; 51956-0001; 51956-0002; 51991-898; 65162-826; 72855-102; 49706-1825; 0078-0503; 63629-2065; 65162-749; 65162-825; 0378-9072; 0781-7309; 12651-118; 64552-4021; 65015-819; 0078-0501; 63629-8846; 0378-9071; 70710-1196; 16714-115; 63629-2066; 50379-0014; 65862-982; 72855-100; 51956-0003; 51991-897; 51991-899; 0781-7313; 63629-2064; 0378-9070; 0078-0502; 16714-116; 63629-8807; 70710-1197
UNII PKI06M3IW0
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C14H22N2O2
CAS Registry Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vertigo04.04.01.003; 17.02.12.0020.004390%
Vomiting07.01.07.0030.023792%
Weight decreased13.15.01.005--
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.003523%Not Available
Application site vesicles12.07.01.009; 08.02.01.009; 23.03.01.0090.001463%Not Available
Application site inflammation12.07.01.024; 08.02.01.0240.001843%Not Available
General physical health deterioration08.01.03.0180.005420%Not Available
Bradyarrhythmia02.03.02.0150.001084%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.003469%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.002276%Not Available
Musculoskeletal stiffness15.03.05.0270.002710%Not Available
Epigastric discomfort07.01.02.0040.000542%Not Available
Application site swelling12.07.01.027; 08.02.01.0270.001192%Not Available
Haemorrhage24.07.01.002--Not Available
Parkinsonian gait17.01.05.005; 08.01.02.0050.000542%Not Available
Fluid intake reduced14.05.10.0010.000813%Not Available
Cognitive disorder17.03.03.003; 19.21.02.0010.005962%
Vascular dementia24.04.06.017; 19.20.04.001; 17.03.01.0030.000542%Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Application site discolouration23.03.03.023; 12.07.01.030; 08.02.01.0300.003685%Not Available
Infrequent bowel movements07.02.02.0110.000542%Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.004--Not Available
Freezing phenomenon17.01.05.0060.002439%Not Available
Appetite disorder19.09.01.002; 14.03.01.0040.000542%Not Available
Cardiac disorder02.11.01.003--Not Available
Feeding disorder14.03.02.003; 19.09.01.0030.000813%Not Available
Malnutrition14.03.02.0040.000542%Not Available
Mental disorder19.07.01.0020.001626%Not Available
Motor dysfunction15.05.06.006; 17.01.02.0310.000542%Not Available
Abnormal behaviour19.01.01.0010.008780%Not Available
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene